Navigation Links
Appropriate medical screening for antimalarials vital to US military personnel
Date:2/19/2008

Malaria is a constant threat to US military personnel operating in Afghanistan, but some troops may face further risk, as epidemiologists have revealed a significant prevalence of contraindications to the safe use of the anti-malarial drug, mefloquine.

Whilst mefloquine has traditionally been considered an effective prevention for long-term malaria chemoprophylaxis, research reported in the open access publication, Malaria Journal, suggests that US military physicians should ensure careful screening processes prior to prescribing and dispensing the drug. Ignoring such contraindications may lead to an increased incidence of psychiatric and neurological disorders.

An epidemiological study from the US Army Center for Health Promotion and Preventive Medicine, led by Remington Nevin, used military medical surveillance and pharmacosurveillance databases to identify contraindications to mefloquine use among a cohort of 11,725 active duty U.S. military personnel, recently deployed to Afghanistan. The study indicates that 9.6 percent of service members deployed to Afghanistan in early 2007 had evidence of psychiatric, medical or pharmacological contraindications to mefloquine, the primary drug used to protect service members from malaria, which is endemic there. It was also reported that females were twice as likely as males to have a contraindication.

This work underscores the importance of proper systematic screening prior to prescribing and dispensing mefloquine, and the need to provide alternatives to mefloquine suitable for long-term administration among deployed U.S. military personnel.

Mefloquine is generally considered safe when prescribed and dispensed appropriately, and when used as directed. However, this study provides evidence that mefloquine is not a suitable option for a significant number of deploying U.S. servicemembers. This study points to the need for enhanced vigilance during pre-deployment medical screening to ensure the appropriate use of this medication, particularly among females, and underscores the need for continued investment in research and development of alternatives to mefloquine that retain the advantages in compliance of a weekly medication.


'/>"/>

Contact: Charlotte Webber
press@biomedcentral.com
44-020-763-19980
BioMed Central
Source:Eurekalert

Related medicine news :

1. Childhood asthma still inappropriately treated in the UK
2. American Heart Association Surgical Supplement Journal Report: Appropriate Hospital Discharge System Can Prevent Future Cardiac Events
3. Study Finds New Version of QIAGENs HPV Test for Developing Countries Could Reduce Risk of Cervical Cancer by More than Half When Combined With Appropriate Treatment
4. Geriatrician Care Guards Against Risk of Inappropriate Meds
5. Appropriate timing in the use of breast shields in children can further reduce MDCT radiation dose
6. MSU engineering team designs innovative medical device
7. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
8. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
9. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
10. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
11. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
Breaking Medicine Technology: